761437-28-9 | NVP-TAE 226

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$57.00	$40.00
5mg	98%	in stock	$208.00	$145.00
10mg	98%	in stock	$310.00	$217.00
25mg	98%	in stock	$660.00	$462.00
50mg	98%	in stock	$1,186.00	$830.00

Description

• Catalog Number: AE04749
• Chemical Name: NVP-TAE 226
• CAS Number: 761437-28-9
• Molecular Formula: C23H25ClN6O3
• Molecular Weight: 468.936
• MDL Number: MFCD12031516
• SMILES: CNC(=O)c1ccccc1Nc1nc(ncc1Cl)Nc1ccc(cc1OC)N1CCOCC1

Computed Properties

• Complexity: 625
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 4.1

Literature

• Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.

  Experimental cell research 20110501

• Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

  Bioorganic & medicinal chemistry letters 20110101

• TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.

  Investigational new drugs 20101201

• Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

  Virology 20100720

• 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20090901

• Cytoskeletal reorganisation, 1alpha,25-dihydroxy vitamin D3 and human MG63 osteoblast maturation.

  Molecular and cellular endocrinology 20090616

• Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

  Molecular cancer therapeutics 20090101

• A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

  Journal of medicinal chemistry 20081211

• TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.

  Oncology reports 20081201

• Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080715

• TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.

  Molecular carcinogenesis 20080301

• Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation.

  PloS one 20080101

• Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

  Cancer research 20071115

• A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

  Molecular carcinogenesis 20070601

• Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.

  Molecular cancer therapeutics 20070401